Search
-
Evolution of bone metastases in patients receiving at least three months of checkpoint inhibitors
(Cancer Immunology, Immunotherapy. vol. 71, n° 11, pp. 2609-2618, 2022-11)Article de revue -
JAK inhibitors and risk of major cardiovascular events or venous thromboembolism: a self-controlled case series study
(European Journal of Clinical Pharmacology. vol. 78, n° 12, pp. 1981-1990, 2022-10-26)Article de revue -
Alopecia areata: Recent advances and emerging therapies
(Annales de Dermatologie et de Venereologie. vol. 149, pp. 222-227, 2022-06-23)Article de revue -
Incidence of cytomegalovirus infection in seropositive kidney transplant recipients treated with everolimus: A randomized, open-label, multicenter phase 4 trial
(American Journal of Transplantation. vol. 22, n° 5, pp. 1430-1441, 2022-01-01)Article de revue -
Everything in moderation or moderating everything? Nutrient balancing in the context of evolution and cancer metabolism
(Biology and Philosophy. vol. 37, n° 2, 2022-04-01)Article de revueOpen access -
Absence of Mortality Differences Between the First and Second COVID-19 Waves in Kidney Transplant Recipients
(Kidney International Reports. vol. 7, n° 12, pp. 2617-2629, 2022-09-21)Article de revueOpen access -
Cancer's second genome: Microbial cancer diagnostics and redefining clonal evolution as a multispecies process: Humans and their tumors are not aseptic, and the multispecies nature of cancer modulates clinical care and clonal evolution
(BioEssays. vol. 44, n° 5, 2022-04-21)Article de revueOpen access -
The Proteome of Antibody-Mediated Rejection: From Glomerulitis to Transplant Glomerulopathy
(Biomedicines. vol. 10, n° 3, 2022-02-28)Article de revueOpen access -
Primary immune responses are negatively impacted by persistent herpesvirus infections in older people: results from an observational study on healthy subjects and a vaccination trial on subjects aged more than 70 years old
(EBioMedicine. vol. 76, pp. 103852, 2022-02-01)Article de revueOpen access -
Efficacy and safety of combination targeted therapies in immune-mediated inflammatory disease: the COMBIO study
(Digestive and Liver Disease. vol. 55, pp. 61-68, 2022-08-16)Article de revue